BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28939078)

  • 1. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
    Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic therapy strategies for head-neck carcinomas: current status].
    Hoffmann TK
    Laryngorhinootologie; 2012 Mar; 91 Suppl 1():S123-43. PubMed ID: 22456917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
    Moskovitz JM; Moy J; Seiwert TY; Ferris RL
    Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immunotherapy for head and neck squamous cell carcinoma.
    Kürten CHL; Ferris RL
    Laryngorhinootologie; 2024 May; 103(S 01):S167-S187. PubMed ID: 38697147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy for head and neck squamous cell carcinoma].
    Chen J; Chen M; Wu HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Busch CJ; Laban S; Knecht R; Hoffmann TK
    HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
    Li J; Luo Z; Jiang S; Li J
    Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overview and prospects of neoadjuvant immunotherapy in head and neck squamous cell carcinoma].
    Liu SY; Song YX; Zhu YM
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):301-305. PubMed ID: 38599644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy for HNSCC : Quo vadis?].
    Döscher J; Busch CJ; Schuler PJ; Laban S
    HNO; 2016 Oct; 64(10):700-7. PubMed ID: 27624904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.
    Bryan RB; Gough MJ; Seung SK; Jutric Z; Weinberg AD; Fox BA; Crittenden MR; Leidner RS; Curti B
    Oral Oncol; 2016 Oct; 61():166-76. PubMed ID: 27614589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Rev Med Suisse; 2006 Oct; 2(81):2216-9. PubMed ID: 17076151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
    Schmitz S; Machiels JP
    Curr Treat Options Oncol; 2016 Jul; 17(7):37. PubMed ID: 27262711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
    Wolf GT; Fee WE; Dolan RW; Moyer JS; Kaplan MJ; Spring PM; Suen J; Kenady DE; Newman JG; Carroll WR; Gillespie MB; Freeman SM; Baltzer L; Kirkley TD; Brandwein HJ; Hadden JW
    Head Neck; 2011 Dec; 33(12):1666-74. PubMed ID: 21284052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of head and neck cancer in the elderly.
    Hartmann S; Grandis JR
    Expert Opin Pharmacother; 2016 Oct; 17(14):1903-21. PubMed ID: 27643444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma.
    Yan S; Liu L; Zhang X; Wei L; Jiang W; Gao X; Yang A; Liu X; Chen W; Chen Y; Li H; Lin Q; Li M; Chen J; Zhang Q; Chen S; Song M
    Clin Transl Oncol; 2024 May; 26(5):1192-1202. PubMed ID: 37989823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Rancoule C; Vallard A; Espenel S; Guy JB; Xia Y; El Meddeb Hamrouni A; Rodriguez-Lafrasse C; Chargari C; Deutsch E; Magné N
    Oral Oncol; 2016 Nov; 62():153-162. PubMed ID: 27623508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.